Innate Pharma (IPHA) Free Cash Flow (2019 - 2025)
Innate Pharma (IPHA) posted quarterly Free Cash Flow of $159313.6 for Q4 2025, down 64.19% year-on-year from $444940.1 in Q4 2024, and down 64.19% on a QoQ basis from $444940.1 in Q4 2024.
Innate Pharma (IPHA) Free Cash Flow (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has reported Free Cash Flow for 7 consecutive years, with $159313.6 the latest figure, recorded in Q4 2025.
- Quarterly Free Cash Flow fell 64.19% year-over-year to $159313.6 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $282212.7 (down 46.32% YoY) and the FY2025 annual result came in at -$60.2 million, down 625.88% from the prior year.
- Free Cash Flow declined to $159313.6 in Q4 2025 per IPHA's latest filing, from $444940.1 in the prior quarter.
- Over the last five years, Free Cash Flow for IPHA reached as high as $1.1 million in Q4 2021 and fell as low as -$322041.1 in Q2 2024.
- A 5-year average of $269315.8 and a median of $159313.6 in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow soared 200.0% — and 2024, when it sank 9533.33%.
- Year by year, Free Cash Flow stood at $1.1 million in 2021, then sank by 42.41% to $608805.5 in 2022, then slumped by 34.39% to $399421.9 in 2023, then advanced by 11.4% to $444940.1 in 2024, then sank by 64.19% to $159313.6 in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered $159313.6, $444940.1, and -$322041.1 for Q4 2025, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Innate Pharma | 157.68 Mn | 157.68 Mn | - | 159,313.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 159,313.60 |
| Dec 31, 2025 | 159,313.60 |
| Dec 31, 2024 | 444,940.12 |
| Dec 31, 2024 | 444,940.12 |
| Jun 30, 2024 | -322,041.06 |
| Jun 30, 2024 | -322,041.06 |
| Dec 31, 2023 | 399,421.95 |
| Dec 31, 2023 | 399,421.95 |
| Jun 30, 2023 | 3,413.86 |
| Jun 30, 2023 | 3,413.86 |
| Dec 31, 2022 | 608,805.54 |
| Dec 31, 2022 | 608,805.54 |
| Jun 30, 2022 | 1,137.95 |
| Jun 30, 2022 | 1,137.95 |
| Dec 31, 2021 | 1.06 Mn |
| Dec 31, 2021 | 1.06 Mn |
| Jun 30, 2021 | 71,691.12 |
| Jun 30, 2021 | 71,691.12 |
| Dec 31, 2020 | 1.03 Mn |
| Dec 31, 2020 | 1.03 Mn |